Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06959225 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 28, 2026 (before its estimated October 9, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Enrollment closed, study ongoing Enrollment target: estimated 550 to confirmed 580 · Site details revised at 101 of 101 sitesv31 Show 2 more changesShow less
    • Enrollment target: estimated 550 to confirmed 580
    • Site details revised at 101 of 101 sites
  2. Site details revised at 1 of 101 sitesv30
  3. Trial sites reduced: 106 → 101 locationsv29
  4. Enrollment target: 400 to 550 Secondary endpoints: 34 to 35v28 Show 1 more changeShow less
    • Secondary endpoints: 34 to 35

    See this version in full on ClinicalTrials.gov ↗

  5. Site details revised at 4 of 106 sitesv27
Show 25 earlier versionsHide 25 earlier versions
  1. Site details revised at 1 of 106 sitesv26
  2. Study sites: 108 to 106v25
  3. Site details revised at 10 of 108 sitesv24
  4. Site details revised at 2 of 108 sitesv23
  5. Study sites: 107 to 108v22
  6. Study sites: 108 to 107v21
  7. Site details revised at 3 of 108 sitesv20
  8. Site details revised at 9 of 108 sitesv19
  9. Site details revised at 8 of 108 sitesv18
  10. Site details revised at 3 of 108 sitesv17
  11. Study sites: 109 to 108v16
  12. Site details revised at 6 of 109 sitesv15
  13. Site details revised at 3 of 109 sitesv14
  14. Site details revised at 2 of 109 sitesv13
  15. Site details revised at 5 of 109 sitesv12
  16. Site details revised at 19 of 109 sitesv11
  17. Site details revised at 1 of 109 sitesv10
  18. Site details revised at 3 of 109 sitesv9
  19. Site details revised at 2 of 109 sitesv8
  20. Site details revised at 2 of 109 sitesv7
  21. Start date changed from estimate of Jun 11, 2025 to Jun 23, 2025 Site details revised at 3 of 109 sitesv6 Show 1 more changeShow less
    • Site details revised at 3 of 109 sites
  22. Site details revised at 2 of 109 sitesv5
  23. Study sites: 108 to 109v4
  24. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 108 · Secondary endpoints: details revised at 1 of 34 entriesv3 Show 2 more changesShow less
    • Study sites: 0 to 108
    • Secondary endpoints: details revised at 1 of 34 entries
  25. Study Status, Referencesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Trial Details
NCT Number NCT06959225
Lead Sponsor Incyte Corporation
Conditions Hidradenitis Suppurativa
Enrollment 580 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov